Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra Announces Global Price Increase7.4.2026 22:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / April 7, 2026 / Formerra, a leading distributor of performance materials, today announced a global price increase of $0.02 / lb on all products. The increase addresses higher operating costs related to rising material costs, exacerbated by the conflict in the Middle East. The adjustment goes into effect on April 15, 2026, or as contracts otherwise allow. Formerra remains committed to maintaining ample inventory levels and the service excellence our valued customers deserve. Customers should contact their Formerra representative for additional information. About Formerra Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce c
Karbon-X Expands Enterprise Climate Platform Through Strategic Partnership with carbon-connect AG7.4.2026 15:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 7, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced a strategic collaboration with carbon-connect AG ("carbon-connect"), a Switzerland-based greenhouse gas (GHG) accounting and sustainability advisory firm. The collaboration marks a continued expansion of Karbon-X's enterprise climate platform, strengthening its carbon measurement, decarbonization advisory, and ongoing monitoring capabilities for corporate and regulated clients. Karbon-X will lead commercial engagement and client integration, incorporating carbon-connect's technical expertise into its end-to-end climate solutions framework. The enhanced service offering includes: Full Scope 1,2, and 3 emissions accounting Emissions abatement planning and implementation Country-specific compliance, ESG, and sustainability reporting Product carbon quantificatio
U.S. Polo Assn. and ESPN Champion the Iconic USPA Gold Cup at the USPA National Polo Center, Hosted by Legendary Commentator Chris Fowler7.4.2026 13:00:00 CEST | Press release
USPA Gold Cup Finals to Air on ESPN and Global Polo Platforms WEST PALM BEACH, FL / ACCESS Newswire / April 7, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the USPA Gold Cup® at the USPA National Polo Center (NPC) in Wellington, Florida on April 5, 2026, Easter Sunday in front of a record crowd at the U.S. Polo Assn. Stadium Field.1. 2026 USPA Gold Cup Winners, Team Pilot (#1 Curtis Pilot - 0, #2 Mackenzie Weisz - 6, #3 Lorenzo Chavanne - 7, #4 Camilo ‘Jeta' Castagnola - 10) on stage with iconic trophy at the USPA National Polo Center - Wellington, Florida 2. Cousins, but rivals on the field - Pilot's Camilo ‘Jeta' Castagnola and La Dolfina Scone's Poroto Cambiaso battle for the ball at the 2026 USPA Gold Cup Final Photo Credit: Augustina Fonda As the second most prestigious tournament in the United States and a critical leg of the Gauntlet of Polo®, the USPA Gold Cup brings together the sport's top players and elite
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush × Zurich 20266.4.2026 15:15:00 CEST | Press release
Building Global Momentum Ahead of Upcoming XRP Tokyo Event PHILADELPHIA, PA / ACCESS Newswire / April 6, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data valuation, monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, today announced that CEO Nathaniel T. Bradley will deliver high-impact keynote presentations at two premier European financial innovation events this spring. On April 22, 2026, Bradley will headline CONV3RGENCE London & The Digital Commonwealth Awards 2026 at the historic Mansion House in London as Flagship Partner. One month later, on May 21, 2026, he will take center stage as Main Strategic Partner at AssetRush × Zurich 2026, GenTwo's flagship "festival of financial innovation" at Kaufleuten Zurich, delivering the opening speech and a major talk on the future of tokenized assets. These back-to-back European keynotes build on Bradley's upcoming presentation at XRP Tokyo
Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 20262.4.2026 18:32:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / April 2, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that CEO Nathaniel (Nate) T. Bradley will present and exhibit the Company's DataValue®, DataScore®, Data Vault Bank® AI Agent, and patented Information Data Exchange® technologies at XRP Tokyo 2026 on April 7, 2026, at Happo-en in Tokyo, Japan. Bradley's presentation, "Data-Driven RWA Tokenization: Unlocking Japan's Trillion-Yen Opportunity on the XRP Ledger," will demonstrate how Datavault AI's platforms support secure, AI-powered tokenization of real estate, commodities, and other high-value assets in Japan's regulation-friendly market. Japan has emerged as Asia's leading real-world asset tokenization market, with institutional platforms such as Progmat (MUFG-backed) managing approximately ¥440 billion (~$2.8 billion USD) in token
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom